HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

Patients began accessing testing today in the first Rexall Pharmacy Walk-In Clinic in Sherwood Park, Alberta. HealthTab will be offering both the Afinion 2™ blood-chemistry analyzer as well as the ID Now™ molecular platform by Abbott Rapid Diagnostics, giving patients quick access to their test results, and allowing for immediate consultation with their pharmacist.

As HealthTab has grown over the last year, it has helped pharmacists screen patients at risk for developing diabetes and cardiovascular conditions, as well as support those already diagnosed to better manage their conditions. With the addition of Rexall within the HealthTab network, patients will have easier access to care and be supported to make meaningful and impactful changes to their health.

About Rexall

With a dynamic history of innovation and growth dating back over a century, Rexall is a leading pharmacy retailer in Canada, dedicated to caring for Canadians' health, one person at a time. Operating approximately 400 pharmacies across Canada, Rexall's 8,000 employees provide compassionate care to patients, becoming their trusted health partners along their wellness journey.

Rexall is part of the Rexall Pharmacy Group ULC and a proud member of the global McKesson Canada Corporation family, a diversified healthcare company with deep roots in supporting patients across Canada.

For more information, visit rexall.ca. Follow us on Twitter: @RexallDrugStore, on Instagram at @RexallDrugStoreOfficial, and @RexallCareNetwork and on Facebook at @RexallDrugStore

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source )
  • Nearly 13.6 Million Canadians are expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source )
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. ( Source )
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, and nearly 12,000 in the UK.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real-time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real-world data (RWD) sets, and third-party app integration through API.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce its agreement with Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOUR ® NEXT GEN and CONTOUR ® NEXT ONE, with Avricore's pharmacy-based point-of-care testing (POCT) platform, HealthTab. Ascensia Diabetes Care is a subsidiary of PHC Holdings Corporation (TSE 6523).

The partnership's objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR ® NEXT GEN or CONTOUR ® NEXT ONE meter the patient uses to the patient's HealthTab account. The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

  • Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.

Pfizer's dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron. After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Invion Limited (ASX:IVX)

Invion Limited

Keep reading...Show less

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.

Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2025 . On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live meeting.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less

Latest Press Releases

Related News

×